National health insurance should cover new anti-platelet drug, says professor

To reduce the mortality rate of thrombotic cardiovascular (CV) events within 12 months in patients with acute coronary syndrome (ACS), the national health insurance needs to cover Brilinta (ticagrelor), a new platelet aggregation inhibitor produced by AstraZeneca.

Professor Chang Yang-su of Yonsei University said in a report that 10 percent of patients treated with percutaneous coronary inte...